Novo Nordisk wins US approval for weight-loss pill

FDA approves oral version of Wegovy

The Food and Drug Administration (FDA) has approved Novo Nordisk’s oral version of the Wegovy weight-loss pill, the first such supplement approved for use.  Novo Nordisk said in a Tuesday release that the GLP-1 pill is intended for once-daily use to “reduce excess body weight and maintain weight reduction long-term and to reduce the risk…

FDA approves Wegovy weight-loss pill from Novo Nordisk

The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy.

Wegovy pill approved by US FDA for weight loss

It marks a first in this new era of weight-loss medications with Wegovy being the only so far to gain approval for a pill version of their shot.

U.S. regulators approve Wegovy pill for weight loss

U.S. regulators on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.

US regulators approve Wegovy pill for weight loss

U.S. regulators have approved a pill version of the weight-loss drug Wegovy. This gives Novo Nordisk an edge over Eli Lilly, whose similar drug is still under review.

Novo Nordisk's Oral Weight-Loss Pill Revolutionizes Obesity Treatment Market

Novo Nordisk's Oral Weight-Loss Pill Revolutionizes Obesity Treatment Market In a significant move to address the burgeoning global obesity crisis, the U.S. Food and Drug Administration has approved Novo Nordisk's oral weight-loss pill, providing a competitive edge over rival Eli Lilly. The semaglutide-based pill, sold under the brand name Wegovy, is a strategic pivot aimed at revitalizing Novo's position in the market.The approval could catalyz…